Author:
Ayass Mohamad Ammar,Tripathi Trivendra,Griko Natalya,Pashkov Victor,Dai Jun,Zhang Jin,Herbert Fabian C.,Ramankutty Nair Ramya,Okyay Tutku,Zhu Kevin,Gassensmith Jeremiah J.,Abi-Mosleh Lina
Abstract
Abstract
Background
The paucity of SARS-CoV-2-specific virulence factors has greatly hampered the therapeutic management of patients with COVID-19 disease. Although available vaccines and approved therapies have shown tremendous benefits, the continuous emergence of new variants of SARS-CoV-2 and side effects of existing treatments continue to challenge therapy, necessitating the development of a novel effective therapy. We have previously shown that our developed novel single-stranded DNA aptamers not only target the trimer S protein of SARS-CoV-2, but also block the interaction between ACE2 receptors and trimer S protein of Wuhan origin, Delta, Delta plus, Alpha, Lambda, Mu, and Omicron variants of SARS-CoV-2. We herein performed in vivo experiments that administer the aptamer to the lungs by intubation as well as in vitro studies utilizing PBMCs to prove the efficacy and safety of our most effective aptamer, AYA2012004_L.
Methods
In vivo studies were conducted in transgenic mice expressing human ACE2 (K18hACE2), C57BL/6J, and Balb/cJ. Flow cytometry was used to check S-protein expressing pseudo-virus-like particles (VLP) uptake by the lung cells and test the immuogenicity of AYA2012004_L. Ames test was used to assess mutagenicity of AYA2012004_L. RT-PCR and histopathology were used to determine the biodistribution and toxicity of AYA2012004_L in vital organs of mice.
Results
We measured the in vivo uptake of VLPs by lung cells by detecting GFP signal using flow cytometry. AYA2012004_L specifically neutralized VLP uptake and also showed no inflammatory response in mice lungs. In addition, AYA2012004_L did not induce inflammatory response in the lungs of Th1 and Th2 mouse models as well as human PBMCs. AYA2012004_L was detectable in mice lungs and noticeable in insignificant amounts in other vital organs. Accumulation of AYA2012004_L in organs decreased over time. AYA2012004_L did not induce degenerative signs in tissues as seen by histopathology and did not cause changes in the body weight of mice. Ames test also certified that AYA2012004_L is non-mutagenic and proved it to be safe for in vivo studies.
Conclusions
Our aptamer is safe, effective, and can neutralize the uptake of VLPs by lung cells when administered locally suggesting that it can be used as a potential therapeutic agent for COVID-19 management.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference53 articles.
1. Martellucci CA, Flacco ME, Cappadona R, Bravi F, Mantovani L, Manzoli L. Sars-cov-2 pandemic: an overview. Adv Biol Regul. 2020;77:100736.
2. Ledford H. Hundreds of covid trials could provide a deluge of new drugs. Nature 2022;25–7.
3. Robinson PC, Liew DF, Tanner HL, Grainger JR, Dwek RA, Reisler RB, Steinman L, Feldmann M, Ho L-P, Hussell T, et al. Covid-19 therapeutics: challenges and directions for the future. Proc Natl Acad Sci. 2022;119(15):2119893119.
4. Information on covid-19 treatment, prevention and research. U.S. Department of Health and Human Services. https://www.covid19treatmentguidelines.nih.gov/
5. Islam S, Islam T, Islam MR. New coronavirus variants are creating more challenges to global healthcare system: a brief report on the current knowledge. Clin Pathol. 2022;15:2632010.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献